Haoxi Health Technology Limited A類普通股是健康科技領域的先驅力量,專注於透過創新的技術驅動解決方案革新醫療保健。該公司利用先進的人工智能和數據分析來提高診斷精確度、簡化治療流程並改善患者管理。憑藉對研發的堅定承諾,Haoxi處於有利地位,能夠應對新興的醫療保健挑戰,為尋求利用這一充滿活力且快速發展市場中的進步的機構投資者帶來巨大的增長機會。
財務指標
營業收入
2026-06-30
$21M
2026-03-31
$33.82M
2025-09-30
$8.84M
2025-03-31
$23.95M
營業支出
2026-06-30
$1.51M
2026-03-31
$7.27M
2025-09-30
$2.31M
2025-03-31
$607.74K
淨利潤
2026-06-30
-$2.65M
2026-03-31
-$6.88M
2025-09-30
$4.1M
2025-03-31
-$232.53K
淨利潤率
2026-06-30
-12.64%
2026-03-31
-20.34%
2025-09-30
46.43%
2025-03-31
-0.97%
每股收益
2026-06-30
--
2026-03-31
--
2025-09-30
$1.14
2025-03-31
$-0.13
息稅折舊攤銷前利潤
2026-06-30
-$2.34M
2026-03-31
-$5.42M
2025-09-30
$4.19M
2025-03-31
$11.61K
有效稅率
2026-06-30
10.27%
2026-03-31
-5.2%
2025-09-30
0.87%
2025-03-31
11.29K%
項目
2026-06-30
2026-03-31
2025-09-30
2025-03-31
營業收入
$21M
$33.82M
$8.84M
$23.95M
營業支出
$1.51M
$7.27M
$2.31M
$607.74K
淨利潤
-$2.65M
-$6.88M
$4.1M
-$232.53K
淨利潤率
-12.64%
-20.34%
46.43%
-0.97%
每股收益
--
--
$1.14
$-0.13
息稅折舊攤銷前利潤
-$2.34M
-$5.42M
$4.19M
$11.61K
有效稅率
10.27%
-5.2%
0.87%
11.29K%
常見問題
HAO is the NYSE Arca-listed ticker for the Invesco China Small Cap ETF, an exchange-traded fund that seeks to track the performance of small-capitalization Chinese companies. Rather than representing a single operating business, HAO holds a basket of equities, giving investors diversified exposure to China's smaller publicly traded firms. The fund is managed by Invesco and trades on U.S. exchanges like a stock, so its price updates throughout the trading day based on the underlying holdings and market demand.
The live price for HAO changes continuously during U.S. market hours, so the most accurate figure is the latest quote shown on this page. That displayed price reflects the most recent trade and may differ from the fund's net asset value because HAO can trade at a slight premium or discount. For real-time context, compare the on-screen price with the day's open, previous close, and any intraday high or low listed alongside it.
Because HAO is an ETF, valuation is best assessed through its portfolio rather than a single P/E ratio. Review the fund's aggregate price-to-earnings and price-to-book ratios, which are typically published by the sponsor, and compare them with broad China or emerging-market benchmarks. Also consider the premium or discount of HAO's market price to its net asset value, since a persistent gap can signal liquidity or demand imbalances. These figures appear on the page's latest data.
HAO trades on NYSE Arca, so it can generally be purchased through a standard brokerage account that offers U.S.-listed ETFs. Place a buy order using the ticker HAO, choosing a market or limit order based on your preference. Fractional shares may be available at some brokers, and commission-free ETF trading is common, though fees vary by platform. Confirm the order type, quantity, and any applicable costs before submitting.
For HAO, performance analysis focuses on the fund rather than a single company's income statement. Review the fund's net asset value history, total return including distributions, and the performance of its underlying small-cap China holdings. The sponsor's fact sheet and annual reports provide sector weightings, top positions, and expense ratio. Comparing HAO's returns with relevant China small-cap indexes helps frame whether its tracking and selection have been effective.
HAO carries concentrated exposure to Chinese small-cap equities, which can be more volatile and less liquid than larger companies. Investors face country and regulatory risk, currency fluctuations between the yuan and dollar, and the possibility of political or policy changes affecting Chinese markets. As an ETF, HAO also has tracking error and premium/discount risk relative to net asset value. These factors can amplify price swings compared with broad U.S. equity funds.